Cell-Easy is pleased to welcome Mrs. Gisele Deblandre, formerly CSO at MaSTherCell, as Chief Scientific Officer
September 28, 2023 08:15 ET
|
CELL-EASY
Cell-Easy, a contract development and manufacturing organization (CDMO) in cell therapy, proudly announces the appointment of Mrs. Gisele Deblandre.
AIM ImmunoTech Selected to Present at the 3rd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care
September 22, 2023 09:05 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., Sept. 22, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced Chris McAleer, Ph.D., Scientific Officer of AIM will present at the...
ImmunOs Therapeutics Appoints Dr. Constanze Guenther as Senior Vice President, CMC and Technical Development
September 19, 2023 04:00 ET
|
AKAMPION
- Former Novartis Executive Director brings significant expertise in manufacturing, operations, and technical development Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA –...
AIM ImmunoTech Announces Report of Complete Topline Data from Roswell Park Comprehensive Cancer Center Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen, with Paclitaxel, for the Treatment of Early-Stage Triple Negative Breast Cancer
September 11, 2023 13:00 ET
|
AIM ImmunoTech Inc.
Complete topline results confirm treatment was well tolerated, with promising clinical activity of pathologic complete response (pCR) + microinvasive residual disease (ypTmic) at 66%, comparable to...
Coherus Completes Surface Oncology Acquisition
September 08, 2023 09:05 ET
|
Coherus BioSciences, Inc.
– Clinical-stage product candidates, casdozokitug and CHS-114, significantly advancenext-generation immuno-oncology portfolio focused on the tumor microenvironment – – I-O combinations will...
AIM ImmunoTech to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023 09:05 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., Sept. 05, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that Thomas K. Equels, Chief Executive Officer of AIM, will present...
Arvinas to Participate in Upcoming Investor Conferences
September 01, 2023 07:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Sept. 01, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Compass Therapeutics to Participate in Upcoming Investor Events
August 30, 2023 08:00 ET
|
Compass Therapeutics
BOSTON, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
Affimed Announces Publication in the Journal mAbs on Leveraging FcRn-pH-HPLC as a Method to Select Bispecific Antibodies with Optimal Developability
August 22, 2023 05:00 ET
|
Affimed N.V.
By coupling the chromatography method FcRn-HPLC to a pH monitor, an optimized FcRn-pH-HPLC methodology was developed allowing correlation of antibodies’ serum half-life with FcRn column dissociation...
AIM ImmunoTech Reports Second Quarter Financial Results and Provides Clinical Pipeline Update
August 15, 2023 06:45 ET
|
AIM ImmunoTech Inc.
– Continued operational execution across pipeline towards multiple clinical and regulatory value-driving milestones expected in the second half of 2023 – Company to host conference call and...